Prot# IMCL CP20-0903: An Open Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advan

Project: Research project

Project Details

StatusFinished
Effective start/end date5/27/11 → 5/27/17

Funding

  • ICON Clinical Research, LLC (IMCL CP20-0903 // IMCL CP20-0903)
  • ImClone Systems Incorporated (IMCL CP20-0903 // IMCL CP20-0903)